<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01840059</url>
  </required_header>
  <id_info>
    <org_study_id>2012HS001B</org_study_id>
    <nct_id>NCT01840059</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>RDT-PEF</acronym>
  <official_title>A Randomised Controlled Trial Investigating the Effect of Transcatheter Renal Sympathetic Denervation on Symptoms and Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether renal sympathetic denervation (RSD)(a
      treatment that lowers the activity of the sympathetic nervous system) is useful in the
      management of patients with heart failure with preserved ejection fraction (HF-PEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing evidence suggests an important role of activation of the sympathetic nervous
      system (SNS) in heart failure with preserved left ventricular ejection fraction. The current
      study aims to evaluate efficacy of renal sympathetic denervation for the modulation of the
      SNS in patients with HF-PEF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>Minnesota Living with Heart Failure Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Exercise Function</measure>
    <time_frame>12 months</time_frame>
    <description>Peak VO2 (Oxygen Uptake) on cardiopulmonary exercise testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Heart Failure Biomarker</measure>
    <time_frame>12 months</time_frame>
    <description>BNP (Natriuretic peptide)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LV (Left Ventricle) filling pressure</measure>
    <time_frame>12 months</time_frame>
    <description>E/E' on echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LV remodelling</measure>
    <time_frame>12 months</time_frame>
    <description>LV mass index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left atrial (LA) size</measure>
    <time_frame>12 months</time_frame>
    <description>LA volume index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Autonomic function</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Heart rate variability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal function</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Urea and Creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular function</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Aorta MRI (Magnetic Resonance Imaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Autonomic function</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>mIBG radiotracer assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neurohormones</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Neurohormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal blood flow</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>Renal MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood pressure</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>ABPM (Ambulatory Blood Pressure Monitoring)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelial function</measure>
    <time_frame>3 and 12 months</time_frame>
    <description>EndoPat</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Cardiac Failure</condition>
  <arm_group>
    <arm_group_label>Renal sympathetic denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation using the Medtronic Symplicity catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HF-PEF patients who will serve as control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal sympathetic denervation</intervention_name>
    <description>A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia</description>
    <arm_group_label>Renal sympathetic denervation</arm_group_label>
    <other_name>Medtronic Symplicity Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  EF&gt;40%

          -  NHYA 2-3

          -  Evidence of HF-PEF (mixture of dilated left atrium, left ventricular hypertrophy,
             raised E/E', elevated LVEDP/PCWP, raised BNP)

        Exclusion Criteria:

          -  Previously documented EF&lt;40%

          -  Hypertrophic, restrictive, dilated cardiomyopathy

          -  Significant valvular heart disease

          -  Unfavourable renal artery anatomy for renal denervation

          -  eGFR&lt;45

          -  Contraindication to MRI

          -  Myocardial infarction, unstable angina or cerebrovascular accident in last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo di Mario</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Sobotka PA, Krum H, BÃ¶hm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012 Jun;14(3):285-92. doi: 10.1007/s11886-012-0258-x. Review.</citation>
    <PMID>22392370</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Failure</keyword>
  <keyword>Autonomic Denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

